// STATE LEGISLATION TRACKER

Ohio HB 462 — Regards student use of a nasal epinephrine delivery device

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Ohio
Bill: HB 462
Filed: 2025-09-23
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Ohio HB 462 appears to address student use of a nasal epinephrine delivery device, likely in a school emergency allergy context. Based on the title and provided subjects/status only, it does not appear to affect compounded peptides, off-label prescribing, telehealth, clinician scope, FDA compounding rules, controlled substances, or prescription monitoring.

Key Points

No apparent change to peptide prescribing or access
No apparent effect on compounded peptides or 503A/503B pharmacies
No apparent telehealth, NP, or naturopathic scope change
No apparent controlled-substance or PDMP impact

What to Watch For

Note Confirm the bill text if later amendments add broader prescribing, school medication, or emergency drug language.

Note Status is unclear because the provided latest-action feed failed, so process tracking should be refreshed later.

Where the Bill Stands

The provided source says the latest action could not be refetched, so the bill's current position in the Ohio process is unknown from the available information.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws